italfarmaco spa

Italfarmaco Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Duchenne

Italfarmaco’s Chief Medical Officer, Dr. Paolo Bettica presented a Late-Breaking News session today at PPMD’s 2022 Annual Conference, announcing positive topline data from its completed Phase 3 EPIDYS trial with Givinostat in boys with Duchenne….

Learn More

Recently Reported Updates from PPMD’s 2021 Virtual Annual Conference

PPMD’s 2021 Virtual Annual Conference: Recently Reported Updates As a new addition to PPMD’s 2021 Virtual Conference, PPMD invited industry partners to share new data with the community live during the Conference in a series…

Learn More

Italfarmaco Announces Topline Data from Phase 2 Trial with Givinostat in Patients with Becker

This afternoon at PPMD’s Virtual Annual Conference, Italfarmaco shared Phase II Study results from the Givinostat trial in patients with Becker. They also issued a press release below. Although they did not meet the primary…

Learn More

October 12, 2020

Italfarmaco Receives FDA Rare Pediatric Disease Designation & Completes EPIDYS Phase 3 Trial Enrollment

Italfarmaco has provided an update on the development of Givinostat, sharing that the FDA has granted a Rare Pediatric Disease designation to Givinostat for the treatment of Duchenne, which allows an expedited review process for…

Learn More

Italfarmaco Provides Update on Advanced-Stage Clinical Development Program with Givinostat in Duchenne

Good news from Italfarmaco! As discussed on our webinar last week, an Independent Data Monitoring Committee (IDMC) has recommended the continuation of their Phase 3 Givinostat trial, determining that the trial is not futile. They…

Learn More

WATCH: Italfarmaco Provides Givinostat Update

Webinar Recording: Italfarmaco Provides Givinostat Update On April 22, 2020, Italfarmaco joined PPMD for a webinar to update the community about Italfarmaco’s development of Givinostat and the recent results of the futility analysis of the…

Learn More

Italfarmaco Shares Community Update on Givinostat Trials & COVID-19

Italfarmaco has shared an update with the community regarding givinostat clinical trials and COVID-19. Read the update from Italfarmaco Dear Duchenne Community, ITALFARMACO team would like to take this opportunity to inform you that we…

Learn More

January 23, 2020

End Duchenne Tour Connect Group Session: Houston, TX

PPMD’s End Duchenne Tour made a stop in Houston, TX on Saturday, January 18. We were joined by over 40 people, including PPMD’s Connect Coordinators for South Texas, several PPMD families, and some of the…

Learn More

January 8, 2020

Italfarmaco Shares Winter 2020 Newsletter

Italfarmaco has shared the Winter 2020 issue of their newsletter, including updates on the Givinostat Development Program. Click here to download.

Learn More

November 4, 2019

End Duchenne Tour Recap: Memphis, TN

PPMD’s End Duchenne Tour made a stop in Memphis, TN on Saturday, October 26. We were joined by over 60 people, including families, an amazing group of volunteers in our kids room, six members of…

Learn More

Join Our Mailing List